320 related articles for article (PubMed ID: 11303059)
1. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.
Huang P; Kehner GB; Cowan A; Liu-Chen LY
J Pharmacol Exp Ther; 2001 May; 297(2):688-95. PubMed ID: 11303059
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.
Ozaki S; Kawamoto H; Itoh Y; Miyaji M; Azuma T; Ichikawa D; Nambu H; Iguchi T; Iwasawa Y; Ohta H
Eur J Pharmacol; 2000 Aug; 402(1-2):45-53. PubMed ID: 10940356
[TBL] [Abstract][Full Text] [Related]
3. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
4. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.
Bloms-Funke P; Gillen C; Schuettler AJ; Wnendt S
Peptides; 2000 Jul; 21(7):1141-6. PubMed ID: 10998549
[TBL] [Abstract][Full Text] [Related]
5. Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome.
Tobacyk J; Parks BJ; Salazar P; Coward LU; Berquist MD; Gorman GS; Brents LK
Drug Alcohol Depend; 2023 Aug; 249():110832. PubMed ID: 37385117
[TBL] [Abstract][Full Text] [Related]
6. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
7. N-terminal modifications leading to peptide ORL1 partial agonists and antagonists.
Judd AK; Kaushanskaya A; Tuttle DJ; Sanchez A; Khroyan T; Polgar W; Toll L
J Pept Res; 2003 Nov; 62(5):191-8. PubMed ID: 14531842
[TBL] [Abstract][Full Text] [Related]
8. Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids.
Butour JL; Moisand C; Mazarguil H; Mollereau C; Meunier JC
Eur J Pharmacol; 1997 Feb; 321(1):97-103. PubMed ID: 9083791
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.
Brown SM; Holtzman M; Kim T; Kharasch ED
Anesthesiology; 2011 Dec; 115(6):1251-60. PubMed ID: 22037640
[TBL] [Abstract][Full Text] [Related]
10. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Olianas MC; Concas D; Onali P
Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
[TBL] [Abstract][Full Text] [Related]
11. Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats.
Janganati V; Salazar P; Parks BJ; Gorman GS; Prather PL; Peterson EC; Alund AW; Moran JH; Crooks PA; Brents LK
Front Pharmacol; 2023; 14():1123261. PubMed ID: 37229250
[No Abstract] [Full Text] [Related]
12. Activities of mixed NOP and mu-opioid receptor ligands.
Spagnolo B; Calo G; Polgar WE; Jiang F; Olsen CM; Berzetei-Gurske I; Khroyan TV; Husbands SM; Lewis JW; Toll L; Zaveri NT
Br J Pharmacol; 2008 Feb; 153(3):609-19. PubMed ID: 18059322
[TBL] [Abstract][Full Text] [Related]
13. Nociceptin activation of the human ORL1 receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors.
Fawzi AB; Zhang H; Weig B; Hawes B; Graziano MP
Eur J Pharmacol; 1997 Oct; 336(2-3):233-42. PubMed ID: 9384238
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of gestational buprenorphine, naloxone, and methadone on mesolimbic mu opioid and ORL1 receptor G protein coupling.
Hou Y; Tan Y; Belcheva MM; Clark AL; Zahm DS; Coscia CJ
Brain Res Dev Brain Res; 2004 Jul; 151(1-2):149-57. PubMed ID: 15246701
[TBL] [Abstract][Full Text] [Related]
15. Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.
Sim LJ; Childers SR
J Comp Neurol; 1997 Oct; 386(4):562-72. PubMed ID: 9378852
[TBL] [Abstract][Full Text] [Related]
16. Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine.
Yu G; Yue YJ; Cui MX; Gong ZH
J Pharmacol Exp Ther; 2006 Jul; 318(1):282-7. PubMed ID: 16569757
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test.
Yamamoto T; Shono K; Tanabe S
J Pharmacol Exp Ther; 2006 Jul; 318(1):206-13. PubMed ID: 16565164
[TBL] [Abstract][Full Text] [Related]
18. Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants.
Grinnell SG; Ansonoff M; Marrone GF; Lu Z; Narayan A; Xu J; Rossi G; Majumdar S; Pan YX; Bassoni DL; Pintar J; Pasternak GW
Synapse; 2016 Oct; 70(10):395-407. PubMed ID: 27223691
[TBL] [Abstract][Full Text] [Related]
19. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors.
Hawkinson JE; Acosta-Burruel M; Espitia SA
Eur J Pharmacol; 2000 Feb; 389(2-3):107-14. PubMed ID: 10688973
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
Spagnolo B; Carrà G; Fantin M; Fischetti C; Hebbes C; McDonald J; Barnes TA; Rizzi A; Trapella C; Fanton G; Morari M; Lambert DG; Regoli D; Calò G
J Pharmacol Exp Ther; 2007 Jun; 321(3):961-7. PubMed ID: 17329552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
